Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

Summary

This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are when compared with a placebo tablet with no medical ingredient. During the study, there will be a 16-week treatment period during which the participants will be asked to take the tablets. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms, itch, sleep, and quality of life.

Timeline

Start

2021-12-13

Primary completion

2023-07-20

Completion

2023-07-26

Outcome

Missed primary endpoint

release “‘이주포란트(LEO 152020)’의 글로벌 임상 2a/b상 초기 주요결과에서 일차 평가 지표를 충족하지 못했다” jw-pharma.co.kr ↗

Drugs

Indications